Interesting perspective....as diseases and tumors continue with a more elaborate description coupled with additional information available, and enter personalized medicine in the picture...will some patients benefit while others end up with little nor no potential drug treatments available...in other words are the days of hit and miss with treatment plans starting to dwindle? BD
It’s the year of less at the big American Society of Clinical Oncology meeting. Rather than buzzing about some promising new drug or treatment, lots of docs are talking about when patients shouldn’t get treated with particular drugs.
“We’re starting to better understand and explore less treatment instead of more for colorectal cancer patients,” M.D. Anderson’s Scott Kopetz told the Health Blog. Researchers are finding ever-more ways to classify tumors. In breast cancer, for example, docs now want to know:
- Is the tumor her-2 positive?
- Is it hormone-sensitive?
- Is the patient pre- or post-menopausal?
0 comments :
Post a Comment